Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Gianluca Gaïdano, Pietro Bulian et al.|Blood|2015Cited by 215
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved SurvivalAntonio Palumbo, Michèle Cavo, Sara Bringhen et al.|Journal of Clinical Oncology|2014Cited by 210
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myelomaAlessandra Larocca, Antonio Palumbo, Sara Bringhen et al.|Leukemia|2016Cited by 46